Clinical Trial Update: Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of oncolytic adenovirus TILT-123 with Avelumab in solid tumors that progressed after anti-PD-(L)1 therapy, including me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma

Drugs mentioned

• Avelumab (avelumab)
• TILT-123 (tilt-123)

Snippet

Sponsor: TILT Biotherapeutics Ltd. | Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING